Supplemental Methods

Definitions
Study Intervention
Post-extubation respiratory support: respiratory support with non-invasive ventilation 
Outcomes:
Ventilator Free Days (VFD): Ventilator-free days are defined as the number of days alive and breathing without assistance from the patient's final receipt of assisted breathing to 28 days after enrollment. If a patient dies before day 28, VFD is 0. If a patient is receiving assisted ventilation at day 28, VFD is 0. If the patient is discharged while receiving assisted ventilation, VFD is 0. If a patient survives to discharge and is never reintubated after enrollment, VFD is 28. Otherwise, VFD is calculated as 28 minus the study day on which the patient ultimately achieved unassisted breathing. All data will be censored at the time of first hospital discharge or 28 days.
In-hospital mortality: In-hospital mortality will be defined as death from any cause prior to hospital discharge. Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable ____N/A___ *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "Attribution-NonCommercial-NoDerivs 3.0 Unported" license.
Protocol for Assessment of Agitation (RASS score)
Protocol for Choice of Analgesia and Sedation in Mechanically Ventilated Patients
• Analgesia a. Intermittent Dosing i. Fentanyl 50 mcg IV push every 15 minutes to goal CPOT <3, then 50mcg IV push every 2 hours as needed to maintain a CPOT < 3
ii. Hydromorphone 0.2 mg IV push every 15 minutes to goal CPOT < 3, then 0.2 mg IV push every 4 hours as needed to maintain CPOT < 3
iii. Morphine 2 mg IV push every 15 minutes to goal CPOT < 3, then 2 mg IV push as needed to maintain CPOT < 3 b. Continuous Infusions i. None
ii. Fentanyl infusion 50mcg/hr, titrate by 25 mcg/hr every 15 minutes to goal CPOT score < 3. Max infusion rate 400mcg/hr. NHO when CPOT target not met with maximum rate.
iii. Morphine infusion 2mg/hr, titrate by 0.5mg/hr every 15 minutes to goal CPOT score < 3. Max infusion rate 20 mg/hr. NHO when CPOT target not met with maximum rate.
• Sedation a. None (if RASS at goal with analgesia-based regimen)
b. Propofol Infusion 5mcg/kg/min, titrate by 5mcg/kg/min every 15 minutes to goal RASS. Max rate of 50mcg/kg/min. NHO when RASS target not met with maximum rate.
c. Dexmedetomidine Infusion 0.2mcg/kg/hr, titrate by 0.1 mcg/kg/hr every 15 minutes to goal RASS. Max rate 1.5 mcg/kg/hr. NHO when RASS target not met with maximum rate.
For propofol intolerance consider one of the following:
d. Midazolam 1mg IV push every 2 hours as needed to meet goal RASS.
e. Midazolam Infusion 0.5mg/hr, titrate by 0.5mg/hr every 15 minutes to achieve goal RASS. Max infusion rate 10mg/hr. NHO when RASS target not met with maximum rate.
(Propofol intolerance refers to propofol infusion syndrome, hemodynamic instability precluding propofol use, elevated creatinine phosphokinase (CPK) >5000 International units/L, triglycerides>500mg/dl, or propofol use >96 hours)
Protocol for Delirium Assessment (CAM-ICU)
Protocol for Early Mobility
Development of the Model for the Primary Analysis
In preparation for PROPER, we collected data on the provision of post-extubation respiratory support and the incidence of reintubation from 420 patients who met inclusion/exclusion criteria for PROPER in a 12-month period (6/1/2015 to 5/31/2016) prior to the trial. Using generalized linear mixed-effects modeling treating the two geographic regions of the unit as clusters and the four 3-month blocks as periods, we calculated the intra-cluster correlation coefficient to be <0.001, the intra-period correlation coefficient to be <0.001, and the intra-cluster intra-period correlation coefficient to be <0.001.
Plan for communication of protocol changes
Any changes to the trial protocol (eg, changes to eligibility criteria, outcomes, analyses) will require a new version of the full trial protocol which will be tracked with the date of the update and the version number of the trial protocol. A list summarizing the changes that are made with each protocol revision will be included at the end of each protocol. The updated protocol will be sent to the Vanderbilt IRB for tracking and approval prior to implementation of the protocol change. At the time of publication, the original trial protocol and the final trial protocol, including the summary of changes made with each protocol change, will be included in the supplementary material for publication.
Patient Privacy and Data Storage
At no time during the course of this study, its analysis, or its publication will patient identities be revealed in any manner. The minimum necessary data containing patient or provider identities is collected. All patients are assigned a unique study ID number for tracking. Data collected from the medical record is entered into the secure online database REDCap. Hard copies of the data collection sheet completed at the time of the airway management event are stored in a locked room until after the completion of enrollment and data cleaning. Once data are verified and the database is locked, all hard copies of data collection forms will be destroyed. All data is maintained in the secure online database REDCap until the time of study publication. At the time of publication, a de-identified database will be generated.
Data Sharing Plan
Upon reasonable request, a completely de-identified data set may be provided by the authors. Request to share data from the PROPER trial should be sent to the principal investigator, Jonathan Casey, MD at Jonathan.D.Casey@vumc.org. The data set will be provided to researchers whose proposed use of the data has been approved by the steering committee and an Institutional Review Board. Figure S1 . PROPER Consort Diagram Template
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